Murphy Capital Management Inc. reduced its position in shares of Celgene Co. (NASDAQ:CELG) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,635 shares of the biopharmaceutical company’s stock after selling 462 shares during the quarter. Murphy Capital Management Inc.’s holdings in Celgene were worth $1,751,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in CELG. First PREMIER Bank bought a new stake in Celgene in the third quarter worth $26,000. Pacer Advisors Inc. boosted its holdings in Celgene by 7.2% in the third quarter. Pacer Advisors Inc. now owns 176,109 shares of the biopharmaceutical company’s stock worth $17,488,000 after purchasing an additional 11,812 shares in the last quarter. We Are One Seven LLC bought a new stake in Celgene in the third quarter worth $292,000. Artemis Investment Management LLP boosted its holdings in Celgene by 2.4% in the third quarter. Artemis Investment Management LLP now owns 145,269 shares of the biopharmaceutical company’s stock worth $14,404,000 after purchasing an additional 3,395 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC boosted its holdings in Celgene by 4.6% in the third quarter. Kohmann Bosshard Financial Services LLC now owns 4,099 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 180 shares in the last quarter. 72.41% of the stock is currently owned by institutional investors.
CELG stock traded up $1.01 during mid-day trading on Friday, reaching $100.82. 1,771,905 shares of the stock traded hands, compared to its average volume of 3,736,602. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $100.42. The business has a 50-day moving average of $97.96 and a two-hundred day moving average of $95.03. The firm has a market capitalization of $70.08 billion, a PE ratio of 13.25, a P/E/G ratio of 0.50 and a beta of 1.42.
Celgene (NASDAQ:CELG) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same quarter last year, the company earned $2.16 earnings per share. The firm’s revenue was up 15.4% on a year-over-year basis. On average, equities research analysts anticipate that Celgene Co. will post 9.96 EPS for the current fiscal year.
In related news, insider Terrie Curran sold 11,338 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now owns 13,493 shares in the company, valued at $1,325,957.11. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.39% of the stock is currently owned by company insiders.
A number of equities research analysts recently issued reports on the stock. Mizuho cut shares of Celgene from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $103.00 to $100.00 in a report on Monday, August 19th. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Cowen reiterated a “hold” rating and issued a $102.00 price objective on shares of Celgene in a report on Tuesday, July 30th. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a report on Tuesday, July 23rd. Finally, BidaskClub upgraded shares of Celgene from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, seventeen have assigned a hold rating and four have assigned a buy rating to the stock. Celgene has a consensus rating of “Hold” and a consensus target price of $94.60.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: How interest rates affect municipal bond prices
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.